Biostar, Kangstem Expand Stem Cell Therapy Pipelines Into AD, Psoriasis
This article was originally published in PharmAsia News
Biostar Group and Kangstem Biotech are expanding their stem cell therapy pipelines via additional indications and a joint development deal, marking a further expansion of South Korea’s activities in the field into the new areas of Alzheimer’s and psoriasis.
You may also be interested in...
US FDA defers action on Spectrum’s approval application for neutropenia candidate Rolontis due to pandemic-related difficulties inspecting partner Hanmi’s plant. The action date has been put back by around four months although the companies stress no CRL has been issued.
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.